BioCentury | Jan 12, 2021
Deals

Sanofi joins the myeloid checkpoint movement with Biond deal

Sanofi is staking claims in next-generation checkpoints through a new deal with Israeli biotech Biond around myeloid checkpoint target ILT2.  The deal with Biond Biologics Ltd., which gives the biotech $125 million up front and...
BioCentury | Nov 13, 2020
Translation in Brief

Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more

Roche’s mAb depletes regulatory T cellsRoche (SIX:ROG; OTCQX:RHHBY) and University College London scientists reported in Nature Cancer that the anti-CD25 mAb RG6292, which is in a Phase I trial in advanced...
BioCentury | Oct 3, 2020
Management Tracks

Li to guide Merck’s next wave of cancer therapies launched by Perlmutter

Dean Li will take over a Merck Research Laboratories that has been transformed by Roger Perlmutter over the past seven years, guiding a pharma that had been struggling with a patent cliff to the company...
BioCentury | Sep 26, 2020
Product Development

Merck’s myeloid data add support for the emerging target class

The myeloid cell targets that have been generating preclinical attention are moving into the clinical arena, and the first look at data from Merck’s ILT4 program provides an early signal that the strategy...
BioCentury | Sep 1, 2020
Deals

Gilead deal clears path for Jounce to advance immuno-oncology programs

Via a deal with Gilead yielding $120 million in upfront cash for rights to a preclinical oncology program, Jounce will extend its cash runway into 2023 as it presses forward with a lead program on...
BioCentury | Jun 6, 2020
Product Development

June 5 Quick Takes: Merck, Tetraphase-Melinta, Apeiron, Neurasic, Jounce, Genmab-J&J

UCB buying Engage for $125M UCB S.A. (Euronext:UCB) acquired Engage Therapeutics Inc. Friday, gaining Staccato alprazolam, a drug-inhaler combo in Phase II testing for the rapid termination of epileptic seizures. Engage will receive $125 million...
BioCentury | May 29, 2020
Finance

May 28 Quick Takes: Illumina leads $70M Ginkgo round; plus Arena, Viela Bio, BioCryst, Progenity and Microbion

Ginkgo financing to support COVID-19 testing New investor Illumina Inc. (NASDAQ:ILMN) led a $70 million round on Thursday for genetic engineering company Ginkgo Bioworks Inc.; existing investors General Atlantic and Viking Global Investors also participated....
BioCentury | Oct 9, 2019
Company News

With Japan submission nearing in NMOSD, Viela picks Mitsubishi as territorial partner

Just days after completing its IPO, Viela will receive another cash infusion from a partnership giving Mitsubishi Tanabe territorial rights to lead program inebilizumab to treat neuromyelitis optical spectrum disorder. Viela Bio Inc. (NASDAQ:VIE) will...
BioCentury | Aug 29, 2019
Financial News

MedImmune-spinout Viela seeking $150M IPO

Autoimmune disease company Viela proposed Thursday to raise up to $150 million in an IPO -- two days after FDA accepted its first BLA for review, and two months after it closed a $75 million...
BioCentury | Jul 24, 2019
Company News

New flexibility and a new Celgene deal for Jounce

With BMS's acquisition of Celgene nearly complete, the big biotech and Jounce ended an immuno-oncology option deal on Tuesday, giving Jounce control over programs that would have overlapped with BMS's pipeline. But the companies will...
Items per page:
1 - 10 of 32